NEW YORK, June 22 (GenomeWeb News) - CeMines, which is developing its molecular fingerprinting technologies for early-stage diagnostics and therapeutics, has relocated from Los Angeles to an expanded facility in La Jolla, Calif., the company said today.
The new 9,000 square-foot facility in La Jolla, Calif., will enable the company to "build automated analysis systems for high-throughput and high-content screening," and to commercialize products, Roger Attick, president and chief executive officer of CeMines, said in a statement.
The company's research division was formerly located at the Ceders Sinai Medical Center in Los Angeles.